1. Retrospective Study of First-Generation Drug-Eluting Stents, Second-Generation Drug- Eluting Stents and Non-Drug Eluting Stent Methods in the Treatment of Native Vessel In-Stent Restenosis in Real-World Clinical Practice 
Drew J. Yates, MBBS, Michael L. Savage, BSc, Darren L. Walters, MBBS, Owen C. Raffel, MBBS 
Heart, Lung and Circulation 
Volume 25, Issue 4, Pages (April 2016)
DOI: /j.hlc
Copyright © 2015 Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ) Terms and Conditions

2. Figure 1 ISR Treatment group versus total adverse cardiac event rate.
1st-generation = first-generation DES group (paclitaxel or sirolimus-eluting stent), 2nd-generation = second-generation DES group (everolimus or zotarolimus-eluting stent), non-DES = balloon angioplasty, cutting balloon or bare-metal stent.
Heart, Lung and Circulation  , DOI: ( /j.hlc )
Copyright © 2015 Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ) Terms and Conditions

3. Figure 2
Kaplan-Meier survival analysis for total adverse cardiac events.
Blue line = first-generation DES treatment group (paclitaxel or sirolimus-eluting stent), Green line = second-generation DES treatment group (everolimus or zotarolimus-eluting stent), Yellow-line = non-DES treatment group (balloon angioplasty, cutting balloon, bare-metal stent).
Heart, Lung and Circulation  , DOI: ( /j.hlc )
Copyright © 2015 Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ) Terms and Conditions